FLT Stock Recent News

Revenue of $10,587,075 in Q2 2025, up 49% year-over-year; gross margin of 32% Adjusted EBITDA loss of $276,259, an 85% year-over-year improvement Current cash balance strengthened to approximately $20M Operational highlights included clearances and demonstrations with defense and energy clients and new commercial wins in forestry and agriculture. Subsequent events included additional NATO-aligned contracts and growth capital TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three and six months ended June 30, 2025 (Q2 2025).

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has completed its previously announced bought deal private placement offering of securities, including the exercise in full of the Underwriter's (as defined below) over-allotment option, of a total of 9,288,462 units of the Company (the “Offered Securities”) at a price of $0.52 per Offered Security for gross proceeds of $4,830,000 (the “Offering”). The Offering was led by institutional investors in Quebec, with strong participation from additional institutional investors across Canada, underscoring the broad confidence in Volatus' strategy and growth potential.The Offering was led by Ventum Financial Corp. as underwriter and sole bookrunner (the “Underwriter”).

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce it has entered into an agreement with Ventum Financial Corp. (the "Underwriter") in connection with a bought deal private placement of 8,076,924 units of the Company (the “Offered Securities”) at a price of $0.52 per Offered Security (the “Issue Price”) for gross proceeds of $4,200,000 (the “Offering”).   Each Offered Security will consist of one common share of the Company and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to acquire one common share of the Company at an exercise price of $0.76 and for a period of 36 months following the Closing Date (as defined below).

TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB), a Canadian leader in aerial intelligence and cargo solutions, is pleased to announce the launch of its Condor XL heavy-lift drone program. Drawing on decades of helicopter operations experience, in-house avionics capabilities, and a renewed focus on rotorcraft-specific training, the company is introducing a next-generation platform designed to meet global demand for autonomous, heavy-lift drone solutions.

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Corp. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) ("Volatus" or the "Company") is pleased to announce that it has been awarded a contract valued at approximately $560,000 CAD to provide advanced training in drone operations and sensor payload utilization to support aerial intelligence. The contract reinforces the Company's role as a trusted provider of mission-critical capabilities for government programs.

TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) welcomes the Government of Canada's pledge to increase defense spending to 2% of GDP and its endorsement of NATO's new target of defense spending to 5% by 2035. These measures signal Canada's strengthened commitment to national sovereignty and collective allied readiness and represent a transformative moment for the Canadian defense and aerospace industry.

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce the successful closing of a $3 million private placement (the “Financing”) from Investissement Québec. Pursuant to the Financing, the Company entered into an amended and restated secured convertible debenture (the “Debenture”) increasing the principal amount of Investissement Québec's original investment of $7.5 million, as announced in the Company's news release dated October 21, 2024, to an aggregate of $10.5 million.

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib